Enfusion downgraded by Goldman with a new price target
$ENFN
Computer Software: Prepackaged Software
Technology
Goldman downgraded Enfusion from Neutral to Sell and set a new price target of $8.00 from $9.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2024 | $11.00 | Overweight | Morgan Stanley |
| 2/28/2024 | $9.00 → $8.00 | Neutral → Sell | Goldman |
| 1/30/2024 | $11.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 11/7/2023 | $9.00 | Neutral | UBS |
| 4/3/2023 | $11.00 | Neutral | Piper Sandler |
| 3/15/2023 | $12.00 | Neutral | JP Morgan |
| 1/4/2023 | $15.00 → $10.00 | Neutral → Underperform | BofA Securities |
| 1/3/2023 | $13.00 → $12.00 | Equal-Weight → Overweight | Morgan Stanley |
Morgan Stanley resumed coverage of Enfusion with a rating of Overweight and set a new price target of $11.00
Goldman downgraded Enfusion from Neutral to Sell and set a new price target of $8.00 from $9.00 previously
JP Morgan downgraded Enfusion from Neutral to Underweight and set a new price target of $9.00 from $11.00 previously
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the prior year. Gross Profit was $36.5 million with a Gross Profit Margin of 69.0%. Adjusted Gross Profit was $36.9 million with an Adjusted Gross Profit Margin of 69.6%. Net Income was $0.2 million with a Net Income Margin of 0.3%. Adjusted EBITDA was $12.3 million, up 25.3% compared to the same period in the prior year. Operating Cash Fl
Investor Conference Call Scheduled for Today at 8:30 a.m. ET Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced their entry into a definitive merger agreement for Clearwater to acquire Enfusion, a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund industry. The purchase price is $11.25 per share, delivered in an approximately equal mix of cash and stock. Additionally, Clearwater will pay $30 million to terminate Enfusion's tax receivable agreement (TRA). This equates to a purchase price of approximately $1.5 billion. This press release features multimedia. View the full release here: https
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2024 financial results as part of its Q3 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 3Q24 Earnings Conference Call Management will host a conference call today, November 4, 2024, at 8:30 AM ET to discuss the results. To pre-register for the live teleconference of the second quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536. The earnings conference call will also
8-K - Enfusion, Inc. (0001868912) (Filer)
425 - Enfusion, Inc. (0001868912) (Subject)
425 - Enfusion, Inc. (0001868912) (Subject)
Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced the preliminary results of the elections made by Enfusion shareholders of record regarding the form of merger consideration (the "Merger Consideration") they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction"). As previously disclosed, the deadline to have made such an election was 5:00 p.m. Eastern Time on April 16, 2025 (the "Election Deadline"). The parties expect to close the Transaction on April 21, 2025, subject to the approval of the Transaction by Enfusion shareholders and the satisfaction or waiver of other customary closing conditions
Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced that the deadline for Enfusion shareholders of record to elect the form of merger consideration (the "Merger Consideration") they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction") is 5:00 p.m. Eastern Time on April 16, 2025 (such deadline, as it may be extended, the "Election Deadline"). Enfusion shareholders who hold shares through a bank, broker or other nominee may be subject to an earlier election deadline and must carefully review and properly complete any election materials they received from their bank, broker or other nominee regardin
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the prior year. Gross Profit was $36.5 million with a Gross Profit Margin of 69.0%. Adjusted Gross Profit was $36.9 million with an Adjusted Gross Profit Margin of 69.6%. Net Income was $0.2 million with a Net Income Margin of 0.3%. Adjusted EBITDA was $12.3 million, up 25.3% compared to the same period in the prior year. Operating Cash Fl
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
FTV Capital, a leading sector-focused growth equity investment firm, today announced its inclusion for the fourth consecutive year on Inc.'s annual Founder-Friendly Investors list, which honors the private equity, venture capital firms and lenders with a track record of backing founder-led companies. This year's list recognizes 269 firms that believe in backing founder-led businesses and helping them thrive, demonstrated by their successful track records of collaboration and remaining actively involved with their portfolio companies to drive growth. "We are honored to be recognized again by Inc. for our ongoing commitment to serving as a collaborative, strategic partner to founders and ent
Appointments of Arman Artuc to Head of Engineering, and Jesper Cordes to Head of Client Services Americas, Will Further Elevate Enfusion's Operations as an Investment Technology Industry Leader Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the appointments of Arman Artuc to Head of Engineering and Jesper Cordes to Head of Client Services Americas. These additions to the leadership team reinforce the company's position as a global leader in investment technology and services, which enables Enfusion to continue to attract top-performing industry experts and innovators to its ranks. Enfusion is s
Transformative acquisition will position ZEMA as global leader in offering high-quality enterprise data management and analytics for the energy and commodities industry ZEMA Global Data Corporation (formerly ZE PowerGroup), a leading provider of enterprise data management and analytics for the commodity and energy sectors, today announced its plans to acquire Morningstar Commodity Data, a provider of commodities and energy data and insights. The transaction is expected to close later this month. The business will serve a diverse portfolio of over 200 enterprises with an expanded product offering and broader geographic operations to support customers around the world. The announcement come